View Older Stories View More Recent Stories

Dec 20, 2023 04:30PM Merck Provides U.S. Regulatory Update on Gefapixant
Dec 20, 2023 06:45AM Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
Dec 19, 2023 06:45AM Merck (MRK) Granted FDA Priority Review for V116
Dec 19, 2023 06:45AM FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Dec 18, 2023 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advance
Dec 18, 2023 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (C
Dec 15, 2023 05:00PM Merck (MRK) Announces FDA Approval of Expanded Indication for KEYTRUDA Plus Padcev for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
Dec 15, 2023 05:00PM FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Ca
Dec 15, 2023 03:34AM Merck (MRK) Announces FDA Approval of WELIREG
Dec 14, 2023 07:00PM FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
Dec 13, 2023 04:55PM Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024
Dec 11, 2023 07:00AM Merck (MRK), Moderna (MRNA) initiate INTerpath-002 Phase 3 trial of V940/KEYTRUDA combo in NSCLC
Dec 11, 2023 06:56AM Merck (MRK) announces positive CVMP opinion on BRAVECTO for dogs
Dec 11, 2023 06:45AM Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
Dec 11, 2023 06:45AM Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected N
Dec 8, 2023 06:45AM Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Dec 7, 2023 06:51AM Merck (MRK) stops Phase 3 KEYLYNK-008 KEYTRUDA trial in NSCLC after it did not not demonstrate improvement in overall survival
Dec 7, 2023 06:45AM Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Dec 7, 2023 06:06AM Merck (MRK) phase 2 KeyVibe-002 trial extended survival but did not reach statistical significance
Dec 7, 2023 06:00AM Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung
Nov 30, 2023 05:00PM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic
Nov 28, 2023 01:17PM Merck Announces First-Quarter 2024 Dividend
Nov 28, 2023 06:48AM Merck (MRK) STRIDE-3 Trial of V116 Vaccine Demonstrated Superior Immunogenicity vs PCV20 in Older Adults
Nov 28, 2023 06:45AM Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV
Nov 21, 2023 06:45AM Merck (MRK) to Acquire Caraway Therapeutics for Up to $610M
Nov 21, 2023 06:45AM Merck to Acquire Caraway Therapeutics, Inc.
Nov 20, 2023 06:45AM Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Nov 16, 2023 05:41PM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenoc
Nov 16, 2023 05:40PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Ade
Nov 10, 2023 07:41AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin
Nov 10, 2023 07:40AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 8, 2023 04:01PM Ligand Reports Third Quarter 2023 Financial Results
Nov 8, 2023 06:45AM Merck to Participate in the Jefferies London Healthcare Conference
Nov 1, 2023 06:50AM Merck to Participate in the UBS BioPharma Conference
Nov 1, 2023 06:46AM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 1, 2023 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 1, 2023 06:30AM KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
Oct 26, 2023 06:30AM Merck Announces Third-Quarter 2023 Financial Results
Oct 22, 2023 10:30AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urot
Oct 21, 2023 08:45AM Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcino
Oct 20, 2023 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Lo
Oct 20, 2023 08:03AM Merck (MRK) Reports KEYTRUDA Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric o
Oct 20, 2023 08:02AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk
Oct 20, 2023 08:01AM KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or
Oct 20, 2023 08:00AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or I
Oct 20, 2023 07:07AM Merck (MRK) in cancer drug deal with Daiichi Sankyo for $5.5 billion upfront, and up to $22 billion total
Oct 19, 2023 07:30PM Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
Oct 17, 2023 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk fo
Oct 17, 2023 06:45AM Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for La
Oct 16, 2023 07:36PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy
View More Recent Stories View Older Stories